Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

Autolus Therapeutics (AUTL) announces an oral presentation and three poster presentations accepted to the 2025 Tandem Meetings Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR ...

Keros Therapeutics (KROS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from Wedbush downgraded the rating on the stock to a ...

A new storage technique can keep protein-based drugs and vaccines stable without keeping them cold. The discovery, led by researchers at Penn State, could eliminate the need for refrigeration for ...

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.

AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics, which spun out of Pfizer ...

Sanofi S.A. Part Cert 0.06% €8.19M ...

Dr. Mohanty will discuss key challenges to modern gene therapy programs for rare disease indications. These will include the general lack of suitable animal models, established clinical endpoints ...

Dyne Therapeutics Inc. 2.97% $1.44B ...

After hours: January 22 at 4:41:30 PM EST Loading Chart for FOLD ...